Scientific Online Resource System

Annual for Hospital Pharmacy

Antibiotic resistance - a new challenge following the COVID-19 pandemic

Stefan Balkanski


Antibiotic resistance represents a huge challenge to mankind, directly affecting human and animal health. The importance of the problem is reinforced by the fact that no new effective antibiotics are expected to be introduced in the next 10-15 years, and the impact of antibiotic resistance on health is expected to increase exponentially in the coming decades.

Various sources describe a significant increase in the use of antibiotics during the COVID-19 pandemic, which hides a danger of the development of highly resistant microorganisms. This can have a negative impact on the fragility of emergency patients attending intensive care units.

This review examines published data on the use of antibiotics during the COVID pandemic and the risk of increasing antibiotic resistance that this may lead to. This is a problem that needs to be taken seriously so that the battle with COVID-19 does not lead to another threat to humanity.


Antibiotic resistance, COVID-19

Full Text


O’Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Resist [Internet]. 2014

Pulcini C, Ergonul O, Can F, Beovic B. Antimicrobial Stewardship [Internet]. London: Elsevier; 2017 [cited 2021 Jul 24].

WHO. Global Action Plan on Antimicrobial Resistance. WHO Tech Rep. 2015;10(9):354–5.

Shankar PR, Balasubramanium R. Antimicrobial Resistance - Global Report on Surveillance. WHO Tech Rep. 2014;

Balasegaram M. Learning from COVID-19 to Tackle Antibiotic Resistance. ACS Infect Dis. 2021;7(4):693–4.

Group WB. Drug-Resistant Infections: A Threat to Our Economic Future. Int Bank Reconstr Dev Bank; Washingt DC. 2017.

COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital | Guidance | NICE.

Rawson TM, Moore LSP, Zhu N, Ranganathan N, Skolimowska K, Gilchrist M, et al. Bacterial and Fungal Coinfection in Individuals with Coronavirus: A Rapid Review to Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis [Internet]. 2020; 71(9):2459–68.

Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020 Dec 1;26(12):1622–9.

Youngs J, Wyncoll D, Hopkins P, Arnold A, Ball J, Bicanic T. Improving antibiotic stewardship in COVID-19: Bacterial coinfection is less common than with influenza. J Infect. 2020; 81(3).

Mahase E. Hydroxychloroquine for covid-19: the end of the line? BMJ. 2020; 369.

Gbinigie K, Frie K. What is the evidence for using macrolide antibiotics to treat COVID-19? The Centre for Evidence-Based Medicine. 2020.

Dhesi Z, Enne VI, Brealey D, Livermore DM, High J, Russell C, et al. Organisms causing secondary pneumonias in COVID-19 patients at 5 UK ICUs as detected with the FilmArray test. 2020.

Dudoignon E, Caméléna F, Deniau B, Habay A, Coutrot M, Ressaire Q, et al. Bacterial Pneumonia in COVID-19 Critically Ill Patients: A Case Series. Clin Infect Dis [Internet]. 2021; 72(5):905–6.

Sheng Z-M, Chertow DS, Ambroggio X, McCall S, Przygodzki RM, Cunningham RE, et al. Autopsy series of 68 cases dying before and during the 1918 influenza pandemic peak. Proc Natl Acad Sci. 2011;108(39):16416–21.

Chien Y-W, Klugman KP, Morens DM. Bacterial Pathogens and Death during the 1918 Influenza Pandemic. 2010; 361(26):2582–3.

Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of antibiotics. Lancet Glob Heal [Internet]. 2020; 8(12).

Lynch C, Mahida N, Gray J. Antimicrobial stewardship: a COVID casualty? Vol. 106, Journal of Hospital Infection. W.B. Saunders Ltd; 2020; 401–3.

Getahun H, Smith I, Trivedi K, Paulin S, Balkhy HH. Tackling antimicrobial resistance in the COVID-19 pandemic. Vol. 98, Bulletin of the World Health Organization. World Health Organization; 2020.

Grigorov E, Karanesheva T. COVID-19 Fake news - how to be protected? Heal Policy Manag. 2020;20(2):17–8.

Zavala-Flores E, Salcedo-Matienzo J. Pre-hospitalary medication in COVID-19 patients from a public hospital in Lima-Peru. Acta Médica Peru. 2020; 37(3):393–5.

Sharifipour E, Shams S, Esmkhani M, Khodadadi J, Fotouhi-Ardakani R, Koohpaei A, et al. Evaluation of bacterial coinfections of the respiratory tract in COVID-19 patients admitted to ICU. BMC Infect Dis 2020; 20(1):1–7.

Laxminarayan R, Matsoso P, Pant S, Brower C, Røttingen J-A, Klugman K, et al. Access to effective antimicrobials: a worldwide challenge. Lancet. 2016; 387(10014):168–75.

Afshinnekoo E, Bhattacharya C, Burguete-García A, Castro-Nallar E, Deng Y, Desnues C, et al. COVID-19 drug practices risk antimicrobial resistance evolution.. The Lancet Microbe. 2021; 135–6.

Sterenczak KA, Barrantes I, Stahnke T, Stachs O, Fuellen G, Undre N. Co-infections: testing macrolides for added benefit in patients with COVID-19. The Lancet Microbe. 2020; 1(8).

Cox MJ, Loman N, Bogaert D, O’Grady J. Co-infections: potentially lethal and unexplored in COVID-19. The Lancet Microbe. 2020; 1(1).

Georgiev K, Kirilov B, Georgieva M. Pharmacological Features of Drugs with Potential Activity Against COVID-19. Sci Pulmonol. 2020;(1):11–9.

Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus. Cell. 2020;182(4):812-827.

Vetter P, Kaiser L, Calmy A, Agoritsas T, Huttner A. Dexamethasone and remdesivir: finding method in the COVID-19 madness. The Lancet Microbe. 2020;1(8).

WHO. Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update. 2020.

Tuccori M, Convertino I, Ferraro S, Cappello E, Valdiserra G, Focosi D, et al. The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance. Drug Saf 2020;43(8):699–709.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62.

Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20(4):425–34.

Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020;55(4):105944.

Ghosh S, Bornman C, Zafer MM. Antimicrobial Resistance Threats in the emerging COVID-19 pandemic: Where do we stand? J Infect Public Health. 2021;14(5):555–60.

Huttner BD, Catho G, Pano-Pardo JR, Pulcini C, Schouten J. COVID-19: don’t neglect antimicrobial stewardship principles! Clin Microbiol Infect. 2020;26(7):808.

Antimicrobial resistance in the age of COVID-19. Nat Microbiol. 2020;5(6):779–779.

Sieswerda E, de Boer MGJ, Bonten MMJ, Boersma WG, Jonkers RE, Aleva RM, et al. Recommendations for antibacterial therapy in adults with COVID-19 – an evidence based guideline. Clin Microbiol Infect. 2021 Jan 1;27(1):61–6.



Article Tools
Email this article (Login required)